Print
  

Transcatheter Aortic Valve Replacement (TAVR) Program: Conception, Today, and Future

This course is for Fairview Employees only

Audience: PT, PTA, OT, COTA, CRB
Course Level: Introductory
Date: Wednesday, October 16, 2013
Check in time: 5:30-6 pm
Class time: 6-8 pm
Location: Fairview Southdale Hospital. International Rooms A and B
6401 France Ave. S., Edina, MN 55435

Contact hours: 2.0

Register for this course

Speaker
GREGORY A. HELMER, M.D., F.A.C.C.,
is a Cardiologist who is active in research, and is the Co-Director of Medical Research for University of Minnesota Physicians Heart at Fairview Community Division Research and Scientific Review. He is presently the Medical Director of UMP-Heart Transcatheter Aortic Valve Replacement (TAVR) program.  Dr. Helmer is a Graduate from University of Michigan Medical School, Ann Arbor, MI and completed Residency at University of MN (Internal Medicine). Site of Fellowship from University of California, San Diego(Cardiology) and University of Minnesota (Interventional Cardiology). Dr. Helmer's special interests include interventional cardiology, as well as angiogenesis for collateral blood vessel growth.   His clinical Research Interests include Cardiovascular CT, Interventional Cardiology, Angiogenesis for collateral vessel development and advances in structural heart disease treatment, balloon valvuloplasty, atrial septal defect closure.  He is a graduate

Course Description
Begins with natural history and etiology of aortic stenosis. Therapy for aortic stenosis medical and surgical. Initial transcatheter development for treatment of aortic stenosis. Review of the PARTNER trial and FDA approval for TAVR in US. UMP-Heart TAVR program development and experience. TAVR procedural details. Future directions for TAVR development.

Objectives
Upon completion of this course the Attendee will be able to describe:
• History of Aortic Stenosis
• Indications for Transcatheter Aortci Valve Replacement (TAVR)
Potential complications for Transcatheter Aortic Valve Replacement (TAVR)
• Future directions for Transcatheter Aortic Valve Replacement (TAVR)

Agenda
5:30-6 p.m.                      Registration/check in
6-6:30 p.m.                      History of Aortic Stenosis
6:30-7:30.pm.                  Indications and complications with Transcatheter Aortic Valve Replacement (TAVR)
7:30-8 p.m.                      Future advancements

 
 Visit Other Fairview Sites 
 
 
(c) 2012 Fairview Health Services. All rights reserved.